-
1
-
-
4744372082
-
Evolution of the Fgf and Fgfr gene families
-
Itoh N, Ornitz D M 2004 Evolution of the Fgf and Fgfr gene families. Trends Genet 20:563-569
-
(2004)
Trends Genet
, vol.20
, pp. 563-569
-
-
Itoh, N.1
Ornitz, D.M.2
-
2
-
-
34250223124
-
Physiology. Sister act
-
Moore DD 2007 Physiology. Sister act. Science 316:1436-1438
-
(2007)
Science
, vol.316
, pp. 1436-1438
-
-
Moore, D.D.1
-
3
-
-
0033763097
-
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23
-
ADHR Consortium 2000 Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet 26:345-348
-
(2000)
Nat Genet
, vol.26
, pp. 345-348
-
-
Consortium, A.1
-
4
-
-
14344279878
-
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia
-
Shimada T, Mizutani S, Muto T, Yoneya T, Hino R, Takeda S, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2001 Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci USA 98:6500-6505
-
(2001)
Proc Natl Acad Sci USA
, vol.98
, pp. 6500-6505
-
-
Shimada, T.1
Mizutani, S.2
Muto, T.3
Yoneya, T.4
Hino, R.5
Takeda, S.6
Takeuchi, Y.7
Fujita, T.8
Fukumoto, S.9
Yamashita, T.10
-
5
-
-
0034703619
-
Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain
-
Yamashita T, Yoshioka M, Itoh N 2000 Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 277:494-498
-
(2000)
Biochem Biophys Res Commun
, vol.277
, pp. 494-498
-
-
Yamashita, T.1
Yoshioka, M.2
Itoh, N.3
-
6
-
-
3242656464
-
FGF23 is processed by proprotein convertases but not by PHEX
-
Benet-Pagès A, Lorenz-Depiereux B, Zischka H, White KE, Econs MJ, Strom T M 2004 FGF23 is processed by proprotein convertases but not by PHEX. Bone 35:455-462
-
(2004)
Bone
, vol.35
, pp. 455-462
-
-
Benet-Pagès, A.1
Lorenz-Depiereux, B.2
Zischka, H.3
White, K.E.4
Econs, M.J.5
Strom, T.M.6
-
7
-
-
0035186837
-
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23
-
White KE, Carn G, Lorenz-Depiereux B, Benet-Pages A, Strom TM, Econs MJ 2001 Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 60:2079-2086
-
(2001)
Kidney Int
, vol.60
, pp. 2079-2086
-
-
White, K.E.1
Carn, G.2
Lorenz-Depiereux, B.3
Benet-Pages, A.4
Strom, T.M.5
Econs, M.J.6
-
8
-
-
33646578195
-
Regulation offibroblast growth factor-23 signaling by klotho
-
Kurosu H, Ogawa Y, Miyoshi M, Yamamoto M, Nandi A, Rosenblatt KP, Baum MG, Schiavi S, Hu MC, Moe OW, Kuro-o M 2006 Regulation offibroblast growth factor-23 signaling by klotho.J Biol Chem 281:6120-6123
-
(2006)
J Biol Chem
, vol.281
, pp. 6120-6123
-
-
Kurosu, H.1
Ogawa, Y.2
Miyoshi, M.3
Yamamoto, M.4
Nandi, A.5
Kp, R.6
Baum, M.G.7
Schiavi, S.8
Hu, M.C.9
Moe, O.W.10
Kuro-O, M.11
-
9
-
-
33845631059
-
Klotho converts canonical FGF receptor into a specific receptor for FGF23
-
Urakawa I, Yamazaki Y, Shimada T, Iijima K, Hasegawa H, Okawa K, Fujita T, Fukumoto S, Yamashita T 2006 Klotho converts canonical FGF receptor into a specific receptor for FGF23. Nature 444:770-774
-
(2006)
Nature
, vol.444
, pp. 770-774
-
-
Urakawa, I.1
Yamazaki, Y.2
Shimada, T.3
Iijima, K.4
Hasegawa, H.5
Okawa, K.6
Fujita, T.7
Fukumoto, S.8
Yamashita, T.9
-
10
-
-
50249114540
-
Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23
-
Yamazaki Y, Tamada T, Kasai N, Urakawa I, Aono Y, Hasegawa H, Fujita T, Kuroki R, Yamashita T, Fukumoto S, Shimada T 2008 Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res 23:1509-1518
-
(2008)
J Bone Miner Res
, vol.23
, pp. 1509-1518
-
-
Yamazaki, Y.1
Tamada, T.2
Kasai, N.3
Urakawa, I.4
Aono, Y.5
Hasegawa, H.6
Fujita, T.7
Kuroki, R.8
Yamashita, T.9
Fukumoto, S.10
Shimada, T.11
-
11
-
-
2142746439
-
FGF-23 is a potent regulator of vitamin D metabolism and phosphate ho-meostasis
-
Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T 2004 FGF-23 is a potent regulator of vitamin D metabolism and phosphate ho-meostasis. J Bone Miner Res 19:429-435
-
(2004)
J Bone Miner Res
, vol.19
, pp. 429-435
-
-
Shimada, T.1
Hasegawa, H.2
Yamazaki, Y.3
Muto, T.4
Hino, R.5
Takeuchi, Y.6
Fujita, T.7
Nakahara, K.8
Fukumoto, S.9
Yamashita, T.10
-
12
-
-
58149394434
-
Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaph-yseal chondrodysplasia
-
Brown WW, Jüppner H, Langman CB, Price H, Farrow EG, White KE, McCormick KL 2009 Hypophosphatemia with elevations in serum fibroblast growth factor 23 in a child with Jansen's metaph-yseal chondrodysplasia. J Clin Endocrinol Metab 94:17-20
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 17-20
-
-
Brown, W.W.1
Jüppner, H.2
Langman, C.B.3
Price, H.4
Farrow, E.G.5
White, K.E.6
McCormick, K.L.7
-
13
-
-
19944430581
-
Mutations that cause osteoglo-phonic dysplasia define novel roles for FGFR1 in bone elongation
-
White KE, Cabral JM, Davis SI, Fishburn T, Evans WE, Ichikawa S, Fields J, Yu X, Shaw NJ, McLellan NJ, McKeown C, Fitzpatrick D, Yu K, Ornitz DM, Econs MJ 2005 Mutations that cause osteoglo-phonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet 76:361-367
-
(2005)
Am J Hum Genet
, vol.76
, pp. 361-367
-
-
White, K.E.1
Cabral, J.M.2
Davis, S.I.3
Fishburn, T.4
Evans, W.E.5
Ichikawa, S.6
Fields, J.7
Yu, X.8
Shaw, N.J.9
McLellan, N.J.10
McKeown, C.11
Fitzpatrick, D.12
Yu, K.13
Ornitz, D.M.14
Econs, M.J.15
-
14
-
-
9144231813
-
Most osteomalacia-as-sociated mesenchymal tumors are a single histopathologic entity: An analysis of 32 cases and a comprehensive review of the literature
-
Folpe AL, Fanburg-Smith JC, Billings SD, Bisceglia M, Bertoni F, Cho JY, Econs MJ, Inwards CY, Jande Beur SM, Mentzel T, Mont-gomery E, Michal M, Miettinen M, Mills SE, Reith JD, O'Connell JX, Rosenberg A E, Rubin BP, Sweet DE, Vinh T N, Wold LE, Wehrli BM, White KE, Zaino RJ, Weiss SW 2004 Most osteomalacia-as-sociated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol 28:1-30
-
(2004)
Am J Surg Pathol
, vol.28
, pp. 1-30
-
-
Folpe, A.L.1
Fanburg-Smith, J.C.2
Billings, S.D.3
Bisceglia, M.4
Bertoni, F.5
Cho, J.Y.6
Econs, M.J.7
Inwards, C.Y.8
Jande Beur, S.M.9
Mentzel, T.10
Mont-Gomery, E.11
Michal, M.12
Miettinen, M.13
Mills, S.E.14
Reith, J.D.15
O'Connell, J.X.16
Rosenberg, A.E.17
Rubin, B.P.18
De, S.19
Vinh, T.N.20
Wold, L.E.21
Wehrli, B.M.22
White, K.E.23
Zaino, R.J.24
Weiss, S.W.25
more..
-
15
-
-
85047693146
-
Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent
-
Berndt T, Craig TA, Bowe AE, Vassiliadis J, Reczek D, Finnegan R, Jan De Beur SM, Schiavi SC, Kumar R 2003 Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent.J Clin Invest 112:785-794
-
(2003)
J Clin Invest
, vol.112
, pp. 785-794
-
-
Berndt, T.1
Craig, T.A.2
Bowe, A.E.3
Vassiliadis, J.4
Reczek, D.5
Finnegan, R.6
Jan De Beur, S.M.7
Schiavi, S.C.8
Kumar, R.9
-
16
-
-
14044267649
-
Fibroblast growth factor 7: An inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors
-
Carpenter TO, Ellis BK, Insogna KL, Philbrick WM, Sterpka J, Shimkets R 2005 Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J Clin Endocrinol Metab 90:1012-1020
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 1012-1020
-
-
Carpenter, T.O.1
Ellis, B.K.2
Insogna, K.L.3
Philbrick, W.M.4
Sterpka, J.5
Shimkets, R.6
-
17
-
-
10744226781
-
MEPE has the properties of an osteoblastic phosphatonin and minhibin
-
Rowe PS, Kumagai Y, Gutierrez G, Garrett IR, Blacher R, Rosen D, Cundy J, Navvab S, Chen D, Drezner MK, Quarles LD, Mundy GR 2004 MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34:303-319
-
(2004)
Bone
, vol.34
, pp. 303-319
-
-
Rowe, P.S.1
Kumagai, Y.2
Gutierrez, G.3
Garrett, I.R.4
Blacher, R.5
Rosen, D.6
Cundy, J.7
Navvab, S.8
Chen, D.9
Drezner, M.K.10
Quarles, L.D.11
Mundy, G.R.12
-
18
-
-
0032865417
-
Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia
-
Fukumoto S, Takeuchi Y, Nagano A, Fujita T 1999 Diagnostic utility of magnetic resonance imaging skeletal survey in a patient with oncogenic osteomalacia. Bone 25:375-377
-
(1999)
Bone
, vol.25
, pp. 375-377
-
-
Fukumoto, S.1
Takeuchi, Y.2
Nagano, A.3
Fujita, T.4
-
19
-
-
0037006672
-
Localisation of mesenchymal tumours by somatostatin receptor imaging
-
Jan de Beur SM, Streeten EA, Civelek AC, McCarthy EF, Uribe L, Marx SJ, Onobrakpeya O, Raisz LG, Watts NB, Sharon M, Levine MA 2002 Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359:761-763
-
(2002)
Lancet
, vol.359
, pp. 761-763
-
-
Jan De Beur, S.M.1
Streeten, E.A.2
Civelek, A.C.3
McCarthy, E.F.4
Uribe, L.5
Marx, S.J.6
Onobrakpeya, O.7
Raisz, L.G.8
Watts, N.B.9
Sharon, M.10
Ma, L.11
-
20
-
-
34147138937
-
PET/CT localizationofphosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia
-
Roarke M C, Nguyen B D 2007 PET/CT localizationofphosphaturic mesenchymal neoplasm causing tumor-induced osteomalacia. Clin Nucl Med 32:300-301
-
(2007)
Clin Nucl Med
, vol.32
, pp. 300-301
-
-
Roarke, M.C.1
Nguyen, B.D.2
-
21
-
-
77956313516
-
Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia
-
Ito N, Shimizu Y, Suzuki H, Saito T, Okamoto T, Hori M, Akahane M, Fukumoto S, Fujita T 2010 Clinical utility of systemic venous sampling of FGF23 for identifying tumours responsible for tumour-induced osteomalacia. J Intern Med 268:390-394
-
(2010)
J Intern Med
, vol.268
, pp. 390-394
-
-
Ito, N.1
Shimizu, Y.2
Suzuki, H.3
Saito, T.4
Okamoto, T.5
Hori, M.6
Akahane, M.7
Fukumoto, S.8
Fujita, T.9
-
22
-
-
4043052503
-
Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia
-
Takeuchi Y, Suzuki H, Ogura S, Imai R, Yamazaki Y, Yamashita T, Miyamoto Y, Okazaki H, Nakamura K, Nakahara K, Fukumoto S, Fujita T 2004 Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 89:3979-3982
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 3979-3982
-
-
Takeuchi, Y.1
Suzuki, H.2
Ogura, S.3
Imai, R.4
Yamazaki, Y.5
Yamashita, T.6
Miyamoto, Y.7
Okazaki, H.8
Nakamura, K.9
Nakahara, K.10
Fukumoto, S.11
Fujita, T.12
-
23
-
-
0029160578
-
A gene (PEX) with homologies to en-dopeptidases is mutated in patients with X-linked hypophos-phatemic rickets
-
The HYP Consortium
-
The HYP Consortium 1995 A gene (PEX) with homologies to en-dopeptidases is mutated in patients with X-linked hypophos-phatemic rickets. Nat Genet 11:130-136
-
(1995)
Nat Genet
, vol.11
, pp. 130-136
-
-
-
24
-
-
20244368616
-
Fibroblast growthfactor23inoncogenic osteomalacia andX-linked hypophosphatemia
-
Jonsson K B, Zahradnik R, Larsson T, White K E, Sugimoto T, Iman-ishiY, Yamamoto T, Hampson G, Koshiyama H, Ljunggren O, Oba K, Yang IM, Miyauchi A, Econs MJ, Lavigne J, Jüppner H 2003 Fibroblast growthfactor23inoncogenic osteomalacia andX-linked hypophosphatemia. N Engl J Med 348:1656-1663
-
(2003)
N Engl J Med
, vol.348
, pp. 1656-1663
-
-
Jonsson, K.B.1
Zahradnik, R.2
Larsson, T.3
White, K.E.4
Sugimoto, T.5
Iman-Ishiy Yamamoto, T.6
Hampson, G.7
Koshiyama, H.8
Ljunggren, O.9
Oba, K.10
Yang, I.M.11
Miyauchi, A.12
Econs, M.J.13
Lavigne, J.14
Jüppner, H.15
-
25
-
-
18744371012
-
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia
-
Yamazaki Y, Okazaki R, Shibata M, Hasegawa Y, Satoh K, Tajima T, Takeuchi Y, Fujita T, Nakahara K, Yamashita T, Fukumoto S 2002 Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 87:4957-4960
-
(2002)
J Clin Endocrinol Metab
, vol.87
, pp. 4957-4960
-
-
Yamazaki, Y.1
Okazaki, R.2
Shibata, M.3
Hasegawa, Y.4
Satoh, K.5
Tajima, T.6
Takeuchi, Y.7
Fujita, T.8
Nakahara, K.9
Yamashita, T.10
Fukumoto, S.11
-
26
-
-
9644303231
-
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice
-
Sitara D, Razzaque MS, Hesse M, Yoganathan S, Taguchi T, Erben RG, Jüppner H, Lanske B 2004 Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol 23:421-432
-
(2004)
Matrix Biol
, vol.23
, pp. 421-432
-
-
Sitara, D.1
Razzaque, M.S.2
Hesse, M.3
Yoganathan, S.4
Taguchi, T.5
Erben, R.G.6
Jüppner, H.7
Lanske, B.8
-
27
-
-
18444375871
-
Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophos-phatemia in vivo
-
Shimada T, Muto T, Urakawa I, Yoneya T, Yamazaki Y, Okawa K, Takeuchi Y, Fujita T, Fukumoto S, Yamashita T 2002 Mutant FGF-23 responsible for autosomal dominant hypophosphatemic rickets is resistant to proteolytic cleavage and causes hypophos-phatemia in vivo. Endocrinology 143:3179-3182
-
(2002)
Endocrinology
, vol.143
, pp. 3179-3182
-
-
Shimada, T.1
Muto, T.2
Urakawa, I.3
Yoneya, T.4
Yamazaki, Y.5
Okawa, K.6
Takeuchi, Y.7
Fujita, T.8
Fukumoto, S.9
Yamashita, T.10
-
28
-
-
0013118819
-
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency
-
Bai XY, Miao D, Goltzman D, Karaplis AC 2003 The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem 278:9843-9849
-
(2003)
J Biol Chem
, vol.278
, pp. 9843-9849
-
-
Bai, X.Y.1
Miao, D.2
Goltzman, D.3
Karaplis, A.C.4
-
29
-
-
34249664523
-
FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets
-
Imel EA, Hui SL, Econs MJ 2007 FGF23 concentrations vary with disease status in autosomal dominant hypophosphatemic rickets. J Bone Miner Res 22:520-526
-
(2007)
J Bone Miner Res
, vol.22
, pp. 520-526
-
-
Imel, E.A.1
Hui, S.L.2
Econs, M.J.3
-
30
-
-
33750454816
-
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism
-
Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE 2006 Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:1310-1315
-
(2006)
Nat Genet
, vol.38
, pp. 1310-1315
-
-
Feng, J.Q.1
Ward, L.M.2
Liu, S.3
Lu, Y.4
Xie, Y.5
Yuan, B.6
Yu, X.7
Rauch, F.8
Davis, S.I.9
Zhang, S.10
Rios, H.11
Drezner, M.K.12
Quarles, L.D.13
Bonewald, L.F.14
White, K.E.15
-
31
-
-
33750427897
-
DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis
-
Lorenz-Depiereux B, Bastepe M, Benet-Pagès A, Amyere M, Wa-genstaller J, Mü ller-Barth U, Badenhoop K, Kaiser SM, Rittmaster RS, Shlossberg AH, Olivares JL, Loris C, Ramos FJ, Glorieux F, Vikkula M, Jüppner H, Strom TM 2006 DMP1 mutations in autosomal recessive hypophosphatemia implicate a bone matrix protein in the regulation of phosphate homeostasis. Nat Genet 38:1248-1250
-
(2006)
Nat Genet
, vol.38
, pp. 1248-1250
-
-
Lorenz-Depiereux, B.1
Bastepe, M.2
Benet-Pagès, A.3
Amyere, M.4
Wa-Genstaller, J.5
Müller-Barth, U.6
Badenhoop, K.7
Kaiser, S.M.8
Rittmaster, R.S.9
Shlossberg, A.H.10
Olivares, J.L.11
Loris, C.12
Ramos, F.J.13
Glorieux, F.14
Vikkula, M.15
Jüppner, H.16
Strom, T.M.17
-
32
-
-
52649142085
-
Pathogenic role of Fgf23 in Dmp1-null mice
-
Liu S, Zhou J, Tang W, Menard R, Feng JQ, Quarles LD 2008 Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endo-crinol Metab 295:E254-E261
-
(2008)
Am J Physiol Endo-crinol Metab
, vol.295
-
-
Liu, S.1
Zhou, J.2
Tang, W.3
Menard, R.4
Feng, J.Q.5
Quarles, L.D.6
-
33
-
-
76049121613
-
Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene
-
Levy-Litan V, Hershkovitz E, Avizov L, Leventhal N, Bercovich D, Chalifa-Caspi V, Manor E, Buriakovsky S, Hadad Y, Goding J, Parvari R 2010 Autosomal-recessive hypophosphatemic rickets is associated with an inactivation mutation in the ENPP1 gene. Am J Hum Genet 86:273-278
-
(2010)
Am J Hum Genet
, vol.86
, pp. 273-278
-
-
Levy-Litan, V.1
Hershkovitz, E.2
Avizov, L.3
Leventhal, N.4
Bercovich, D.5
Chalifa-Caspi, V.6
Manor, E.7
Buriakovsky, S.8
Hadad, Y.9
Goding, J.10
Parvari, R.11
-
34
-
-
76049105171
-
Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophos-phatemic rickets
-
Lorenz-Depiereux B, Schnabel D, Tiosano D, HäuslerG, Strom TM 2010 Loss-of-function ENPP1 mutations cause both generalized arterial calcification of infancy and autosomal-recessive hypophos-phatemic rickets. Am J Hum Genet 86:267-272
-
(2010)
Am J Hum Genet
, vol.86
, pp. 267-272
-
-
Lorenz-Depiereux, B.1
Schnabel, D.2
Tiosano, D.3
Häusler, G.4
Strom, T.M.5
-
35
-
-
43149103153
-
Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: Proposal of diagnostic criteria using FGF23 measurement
-
Endo I, Fukumoto S, Ozono K, Namba N, Tanaka H, Inoue D, Minagawa M, Sugimoto T, Yamauchi M, Michigami T, Matsu-moto T 2008 Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone 42:1235-1239
-
(2008)
Bone
, vol.42
, pp. 1235-1239
-
-
Endo, I.1
Fukumoto, S.2
Ozono, K.3
Namba, N.4
Tanaka, H.5
Inoue, D.6
Minagawa, M.7
Sugimoto, T.8
Yamauchi, M.9
Michigami, T.10
Matsu-Moto, T.11
-
36
-
-
16244364756
-
The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI)
-
Ruf N, Uhlenberg B, Terkeltaub R, Nurnberg P, Rutsch F 2005 The mutational spectrum of ENPP1 as arising after the analysis of 23 unrelated patients with generalized arterial calcification of infancy (GACI). Hum Mutat 25:98
-
(2005)
Hum Mutat
, vol.25
, pp. 98
-
-
Ruf, N.1
Uhlenberg, B.2
Terkeltaub, R.3
Nurnberg, P.4
Rutsch, F.5
-
37
-
-
0042166167
-
Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification
-
Rutsch F, Ruf N, Vaingankar S, Toliat MR, Suk A, Höhne W, Schauer G, Lehmann M, Roscioli T, Schnabel D, Epplen JT, Knisely A, Superti-Furga A, McGill J, Filippone M, Sinaiko AR, Vallance H, Hinrichs B, Smith W, Ferre M, Terkeltaub R, Nürnberg P 2003 Mutations in ENPP1 are associated with 'idiopathic' infantile arterial calcification. Nat Genet 34:379-381
-
(2003)
Nat Genet
, vol.34
, pp. 379-381
-
-
Rutsch, F.1
Ruf, N.2
Vaingankar, S.3
Toliat, M.R.4
Suk, A.5
Höhne, W.6
Schauer, G.7
Lehmann, M.8
Roscioli, T.9
Schnabel, D.10
Epplen, J.T.11
Knisely, A.12
Superti-Furga, A.13
McGill, J.14
Filippone, M.15
Sinaiko, A.R.16
Vallance, H.17
Hinrichs, B.18
Smith, W.19
Ferre, M.20
Terkeltaub, R.21
Nürnberg, P.22
more..
-
38
-
-
68149120891
-
Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond in-fancyingeneralized arterial calcificationofinfancy
-
Rutsch F, Böyer P, Nitschke Y, Ruf N, Lorenz-Depierieux B, Wit-tkampf T, Weissen-Plenz G, Fischer RJ, Mughal Z, Gregory JW, Davies JH, Loirat C, Strom TM, Schnabel D, Nürnberg P, Ter-keltaub R 2008 Hypophosphatemia, hyperphosphaturia, and bisphosphonate treatment are associated with survival beyond in-fancyingeneralized arterial calcificationofinfancy. Circ Cardiovasc Genet 1:133-140
-
(2008)
Circ Cardiovasc Genet
, vol.1
, pp. 133-140
-
-
Rutsch, F.1
Böyer, P.2
Nitschke, Y.3
Ruf, N.4
Lorenz-Depierieux, B.5
Wit-Tkampf, T.6
Weissen-Plenz, G.7
Fischer, R.J.8
Mughal, Z.9
Gregory, J.W.10
Davies, J.H.11
Loirat, C.12
Strom, T.M.13
Schnabel, D.14
Nürnberg, P.15
Ter-Keltaub, R.16
-
39
-
-
0036829257
-
Bone mineralization in polyostotic fibrous dysplasia: Histomorphometric analysis
-
Terpstra L, Rauch F, Plotkin H, Travers R, Glorieux FH 2002 Bone mineralization in polyostotic fibrous dysplasia: histomorphometric analysis. J Bone Miner Res 17:1949-1953
-
(2002)
J Bone Miner Res
, vol.17
, pp. 1949-1953
-
-
Terpstra, L.1
Rauch, F.2
Plotkin, H.3
Travers, R.4
Glorieux, F.H.5
-
40
-
-
85047691059
-
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting
-
Riminucci M, Collins M T, Fedarko N S, Cherman N, Corsi A, White KE, Waguespack S, Gupta A, Hannon T, Econs MJ, Bianco P, Ge-hron Robey P 2003 FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest 112:683-692
-
(2003)
J Clin Invest
, vol.112
, pp. 683-692
-
-
Riminucci, M.1
Collins, M.T.2
Fedarko, N.S.3
Cherman, N.4
Corsi, A.5
White, K.E.6
Waguespack, S.7
Gupta, A.8
Hannon, T.9
Econs, M.J.10
Bianco, P.11
Ge-Hron Robey, P.12
-
41
-
-
16344378643
-
Elevated fibroblast growth factor-23inhypophosphatemic linear nevus sebaceous syndrome
-
Hoffman WH, Jueppner HW, Deyoung BR, O'dorisio M S, Given KS 2005 Elevated fibroblast growth factor-23inhypophosphatemic linear nevus sebaceous syndrome.Am JMed Genet A 134:233-236
-
(2005)
Am JMed Genet A
, vol.134
, pp. 233-236
-
-
Hoffman, W.H.1
Jueppner, H.W.2
Deyoung, B.R.3
O'Dorisio, M.S.4
Given, K.S.5
-
42
-
-
77954424487
-
Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets
-
Sethi SK, Hari P, Bagga A 2010 Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets. Pediatr Nephrol 25:1577-1578
-
(2010)
Pediatr Nephrol
, vol.25
, pp. 1577-1578
-
-
Sethi, S.K.1
Hari, P.2
Bagga, A.3
-
43
-
-
67650215157
-
FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: A prospective study
-
Schouten BJ, Hunt PJ, Livesey JH, Frampton CM, Soule SG 2009 FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 94:2332-2337
-
(2009)
J Clin Endocrinol Metab
, vol.94
, pp. 2332-2337
-
-
Schouten, B.J.1
Hunt, P.J.2
Livesey, J.H.3
Frampton, C.M.4
Soule, S.G.5
-
44
-
-
68849127439
-
Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: Another form of FGF23-related hypophosphatemia
-
Shimizu Y, Tada Y, Yamauchi M, Okamoto T, Suzuki H, Ito N, Fukumoto S, Sugimoto T, Fujita T 2009 Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 45:814-816
-
(2009)
Bone
, vol.45
, pp. 814-816
-
-
Shimizu, Y.1
Tada, Y.2
Yamauchi, M.3
Okamoto, T.4
Suzuki, H.5
Ito, N.6
Fukumoto, S.7
Sugimoto, T.8
Fujita, T.9
-
45
-
-
0023684611
-
Correlations of serum concentrations of 1, 25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis
-
Lyles KW, Halsey DL, Friedman NE, Lobaugh B 1988 Correlations of serum concentrations of 1, 25-dihydroxyvitamin D, phosphorus, and parathyroid hormone in tumoral calcinosis. J Clin Endocrinol Metab 67:88-92
-
(1988)
J Clin Endocrinol Metab
, vol.67
, pp. 88-92
-
-
Lyles, K.W.1
Halsey, D.L.2
Friedman, N.E.3
Lobaugh, B.4
-
46
-
-
1642416884
-
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism
-
Shimada T, Kakitani M, Yamazaki Y, Hasegawa H, Takeuchi Y, Fujita T, Fukumoto S, Tomizuka K, Yamashita T 2004 Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest 113: 561-568
-
(2004)
J Clin Invest
, vol.113
, pp. 561-568
-
-
Shimada, T.1
Kakitani, M.2
Yamazaki, Y.3
Hasegawa, H.4
Takeuchi, Y.5
Fujita, T.6
Fukumoto, S.7
Tomizuka, K.8
Yamashita, T.9
-
47
-
-
2642546399
-
Mutations in GALNT3, encoding a protein involved in O-linked glyco-sylation, cause familial tumoral calcinosis
-
Topaz O, Shurman DL, Bergman R, Indelman M, Ratajczak P, Mizrachi M, Khamaysi Z, Behar D, Petronius D, Friedman V, Ze-likovic I, Raimer S, Metzker A, Richard G, Sprecher E 2004 Mutations in GALNT3, encoding a protein involved in O-linked glyco-sylation, cause familial tumoral calcinosis. Nat Genet 36:579-581
-
(2004)
Nat Genet
, vol.36
, pp. 579-581
-
-
Topaz, O.1
Shurman, D.L.2
Bergman, R.3
Indelman, M.4
Ratajczak, P.5
Mizrachi, M.6
Khamaysi, Z.7
Behar, D.8
Petronius, D.9
Friedman, V.10
Ze-Likovic, I.11
Raimer, S.12
Metzker, A.13
Richard, G.14
Sprecher, E.15
-
48
-
-
33846528466
-
Hyperostosis-hyperphosphatemia syndrome: A congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23
-
Frishberg Y, Ito N, Rinat C, Yamazaki Y, Feinstein S, Urakawa I, Navon-Elkan P, Becker-Cohen R, Yamashita T, Araya K, Igarashi T, Fujita T, Fukumoto S 2007 Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. J Bone Miner Res 22:235-242
-
(2007)
J Bone Miner Res
, vol.22
, pp. 235-242
-
-
Frishberg, Y.1
Ito, N.2
Rinat, C.3
Yamazaki, Y.4
Feinstein, S.5
Urakawa, I.6
Navon-Elkan, P.7
Becker-Cohen, R.8
Yamashita, T.9
Araya, K.10
Igarashi, T.11
Fujita, T.12
Fukumoto, S.13
-
49
-
-
0037234565
-
All in the family: The UDP-Gal N Ac:polypeptide N- acetylgalactosaminyltransferases
-
Ten Hagen KG, Fritz TA, Tabak LA 2003 All in the family: the UDP-Gal N Ac:polypeptide N-acetylgalactosaminyltransferases. Glycobiology 13:1R-16R
-
(2003)
Glycobiology
, vol.13
-
-
Ten Hagen, K.G.1
Fritz, T.A.2
Tabak, L.A.3
-
50
-
-
33745828096
-
Polypeptide Gal N Ac-transferaseT3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation
-
Kato K, Jeanneau C, Tarp M A, Benet-PagèsA, Lorenz-Depiereux B, Bennett EP, Mandel U, Strom TM, Clausen H 2006 Polypeptide Gal N Ac-transferaseT3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation. J Biol Chem 281:18370-18377
-
(2006)
J Biol Chem
, vol.281
, pp. 18370-18377
-
-
Kato, K.1
Jeanneau, C.2
Tarp, M.A.3
Benet-Pagèsa Lorenz-Depiereux, B.4
Bennett, E.P.5
Mandel, U.6
Strom, T.M.7
Clausen, H.8
-
51
-
-
26244454531
-
A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis
-
Araya K, Fukumoto S, Backenroth R, Takeuchi Y, Nakayama K, Ito N, Yoshii N, Yamazaki Y, Yamashita T, Silver J, Igarashi T, Fujita T 2005 A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis.JClin Endocrinol Metab 90:5523-5527
-
(2005)
J Clin Endocrinol Metab
, vol.90
, pp. 5523-5527
-
-
Araya, K.1
Fukumoto, S.2
Backenroth, R.3
Takeuchi, Y.4
Nakayama, K.5
Ito, N.6
Yoshii, N.7
Yamazaki, Y.8
Yamashita, T.9
Silver, J.10
Igarashi, T.11
Fujita, T.12
-
52
-
-
13544270218
-
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia
-
Benet-Pagès A, Orlik P, Strom TM, Lorenz-Depiereux B 2005 An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet 14:385-390
-
(2005)
Hum Mol Genet
, vol.14
, pp. 385-390
-
-
Benet-Pagès, A.1
Orlik, P.2
Strom, T.M.3
Lorenz-Depiereux, B.4
-
53
-
-
4544357727
-
FGF-23 is elevated by chronic hyperphosphatemia
-
Gupta A, Winer K, Econs MJ, Marx SJ, Collins MT 2004 FGF-23 is elevated by chronic hyperphosphatemia. J Clin Endocrinol Metab 89:4489-4492
-
(2004)
J Clin Endocrinol Metab
, vol.89
, pp. 4489-4492
-
-
Gupta, A.1
Winer, K.2
Econs, M.J.3
Marx, S.J.4
Collins, M.T.5
-
55
-
-
34848871595
-
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis
-
Ichikawa S, Imel EA, Kreiter ML, Yu X, Mackenzie DS, Sorenson AH, Goetz R, Mohammadi M, White KE, Econs MJ 2007 A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest 117:2684-2691
-
(2007)
J Clin Invest
, vol.117
, pp. 2684-2691
-
-
Ichikawa, S.1
Imel, E.A.2
Kreiter, M.L.3
Yu, X.4
MacKenzie, D.S.5
Sorenson, A.H.6
Goetz, R.7
Mohammadi, M.8
White, K.E.9
Econs, M.J.10
-
56
-
-
0344945402
-
Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers
-
Larsson T, Nisbeth U, Ljunggren O, Jüppner H, Jonsson KB 2003 Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 64:2272-2279
-
(2003)
Kidney Int
, vol.64
, pp. 2272-2279
-
-
Larsson, T.1
Nisbeth, U.2
Ljunggren, O.3
Jüppner, H.4
Jonsson, K.B.5
-
57
-
-
77649227621
-
Fibroblast growth factor-23 and early decrements in kidney function: The Heart and Soul Study
-
Ix JH, Shlipak MG, Wassel CL, Whooley MA 2010 Fibroblast growth factor-23 and early decrements in kidney function: the Heart and Soul Study. Nephrol Dial Transplant 25:993-997
-
(2010)
Nephrol Dial Transplant
, vol.25
, pp. 993-997
-
-
Ix, J.H.1
Shlipak, M.G.2
Wassel, C.L.3
Ma, W.4
-
58
-
-
27744545673
-
Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease
-
Gutierrez O, Isakova T, Rhee E, Shah A, Holmes J, Collerone G, Jüppner H, Wolf M 2005 Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 16:2205-2215
-
(2005)
J Am Soc Nephrol
, vol.16
, pp. 2205-2215
-
-
Gutierrez, O.1
Isakova, T.2
Rhee, E.3
Shah, A.4
Holmes, J.5
Collerone, G.6
Jüppner, H.7
Wolf, M.8
-
59
-
-
36849017126
-
The parathyroid is a target organ for FGF23 in rats
-
Ben-Dov IZ, Galitzer H, Lavi-Moshayoff V, Goetz R, Kuro-o M, Mohammadi M, Sirkis R, Naveh-Many T, Silver J 2007 The parathyroid is a target organ for FGF23 in rats. J Clin Invest 117:4003-4008
-
(2007)
J Clin Invest
, vol.117
, pp. 4003-4008
-
-
Ben-Dov, I.Z.1
Galitzer, H.2
Lavi-Moshayoff, V.3
Goetz, R.4
Kuro-O, M.5
Mohammadi, M.6
Sirkis, R.7
Naveh-Many, T.8
Silver, J.9
-
60
-
-
35848947037
-
Fibroblast growth factor-23 regulates parathyroid hormone and 1 a-hydroxylase expression in cultured bovine parathyroid cells
-
Krajisnik T, Bjorklund P, Marsell R, Ljunggren O, Akerstrom G, Jonsson KB, Westin G, Larsson TE 2007 Fibroblast growth factor-23 regulates parathyroid hormone and 1 a-hydroxylase expression in cultured bovine parathyroid cells. J Endocrinol 195:125-131
-
(2007)
J Endocrinol
, vol.195
, pp. 125-131
-
-
Krajisnik, T.1
Bjorklund, P.2
Marsell, R.3
Ljunggren, O.4
Akerstrom, G.5
Jonsson, K.B.6
Westin, G.7
Larsson, T.E.8
-
61
-
-
74449086740
-
Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients
-
Komaba H, Goto S, Fujii H, Hamada Y, Kobayashi A, Shibuya K, Tominaga Y, Otsuki N, Nibu K, Nakagawa K, Tsugawa N, Okano T, Kitazawa R, Fukagawa M, Kita T 2010 Depressed expression of Klotho and FGF receptor 1 in hyperplastic parathyroid glands from uremic patients. Kidney Int 77:232-238
-
(2010)
Kidney Int
, vol.77
, pp. 232-238
-
-
Komaba, H.1
Goto, S.2
Fujii, H.3
Hamada, Y.4
Kobayashi, A.5
Shibuya, K.6
Tominaga, Y.7
Otsuki, N.8
Nibu, K.9
Nakagawa, K.10
Tsugawa, N.11
Okano, T.12
Kitazawa, R.13
Fukagawa, M.14
Kita, T.15
-
62
-
-
77957668094
-
FGF23: More than a regulator of renal phosphate handling?
-
Jüppner H, Wolf M, Salusky IB 2010 FGF23: more than a regulator of renal phosphate handling? J Bone Miner Res 25:2091-2097
-
(2010)
J Bone Miner Res
, vol.25
, pp. 2091-2097
-
-
Jüppner, H.1
Wolf, M.2
Salusky, I.B.3
-
63
-
-
77956539995
-
Forging forward with 10 burning questions on FGF23 in kidney disease
-
Wolf M 2010 Forging forward with 10 burning questions on FGF23 in kidney disease. J Am Soc Nephrol 21:1427-1435
-
(2010)
J Am Soc Nephrol
, vol.21
, pp. 1427-1435
-
-
Wolf, M.1
|